Efficacy and Safety of Prolonged-Release Lanreotide in Patients With Gastrointestinal Neuroendocrine Tumors and Hormone-Related Symptoms - Concepedia

Concepedia

Publication | Closed Access

Efficacy and Safety of Prolonged-Release Lanreotide in Patients With Gastrointestinal Neuroendocrine Tumors and Hormone-Related Symptoms

223

Citations

16

References

1999

Year

A.N.M. Wymenga, Barbro Eriksson, Pasi Salmela, M. B. Jacobsen, E.J.D.G. van Cutsem, René Fiasse, Matti Välimäki, J. Renstrup, Elisabeth G.E. de Vries, Kjell E. Öberg

Journal of Clinical Oncology

Abstract

Lanreotide PR is a well-tolerated somatostatin analog with significant clinical, biochemical, and antitumor effects that bring about a significant improvement in QOL for patients with neuroendocrine tumors.

References

	Year	Citations

Page 1